<DOC>
	<DOCNO>NCT00752739</DOCNO>
	<brief_summary>RATIONALE : Selenium may prevent slow growth prostate cancer . PURPOSE : This randomized phase II trial study well selenium work treat patient prostate cancer .</brief_summary>
	<brief_title>Selenium Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To investigate ability selenium prevent progression patient adenocarcinoma prostate . - To investigate ability selenium effectively modulate biomarkers prostate cancer . - To determine selenium modifies progression prostate cancer base analysis initial biopsy , subsequent blood biomarkers , urological symptom . - To establish safety chronic supplementation selenium patient . OUTLINE : Patients stratify accord Gleason score ( low v moderate ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive oral placebo daily 48 month absence disease progression unacceptable toxicity . - Arm II : Patients receive low-dose oral selenium daily 48 month absence disease progression unacceptable toxicity . - Arm III : Patients receive high-dose oral selenium daily 48 month absence disease progression unacceptable toxicity . Blood tissue sample collect periodically biomarker laboratory study . Blood sample analyze level prostate-specific antigen , chromogranin A , alkaline phosphatase , alpha tocopherol , lycopene , vitamin ; level selenium atomic absorption spectrometry ; oxidative damage DNA . Tissue sample analyze level Bcl-2 , p53 , Ki-67 , thioredoxin reductase , thioredoxin , glutathione peroxidase immunohistochemistry apoptotic index TUNEL assay . Patients complete urological symptom questionnaire questionnaires periodically .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven adenocarcinoma prostate within past 48 month Prostatespecific antigen &lt; 50 ng/mL Gleason score &lt; 8 Currently undergo `` watchful waiting '' prostate cancer No metastatic disease PATIENT CHARACTERISTICS : Life expectancy ≥ 3 year AST ALT ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 1.5 time ULN Bilirubin ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN No malignancy within past 5 year , except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : No prior hormone therapy , radiotherapy , chemotherapy , surgery prostate cancer At least 90 day since prior concurrent selenium ( dietary supplement part multivitamin ) exceed 50 mcg/day</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>